(MedPage Today) — Patients with EGFR-mutated non-small cell lung cancer (NSCLC) who progressed on first-line osimertinib (Tagrisso) had better progression-free survival (PFS) in second line when they continued osimertinib plus chemotherapy, a…
Source link : https://www.medpagetoday.com/meetingcoverage/iaslc/117361
Author :
Publish date : 2025-09-08 18:35:00
Copyright for syndicated content belongs to the linked Source.
